Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space.

Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomb...

- Reuters 

Eli Lilly's launch of the competitively priced Zepbound has triggered a 4.9% drop in Hims & Hers' stock. This has r...

Morgan Stanley analyst Terence Flynn reiterates Eli Lilly (NYSE:LLY) with a Overweight and maintains $1106 price target.

Eli Lilly launches low-dose Zepbound vials for weight loss, offering 2.5 mg and 5 mg options for self-pay patients. These vials...

A four-week supply of the 2.5 mg Zepbound single-dose vial is $399 ($99.75 per vial), and a four-week supply of the 5 mg dose i...

State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system t...